Do analysts rate APLM or DTIL?

Precision BioSciences has a consensus target price of $32.25, indicating a potential upside of 294.25%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has preferable earnings & valuation, APLM or DTIL?

Apollomics has higher earnings, but lower revenue than Precision BioSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Precision BioSciences $34.26M 6.16 -$45.72M -$3.67 N/A

Does the media prefer APLM or DTIL?

In the previous week, Precision BioSciences had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.28 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer APLM or EQ?

Equillium has a consensus price target of $7.57, indicating a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Equillium 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has preferable valuation and earnings, APLM or EQ?

Apollomics has higher earnings, but lower revenue than Equillium. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Equillium $41.10M 4.48 -$22.40M -$0.32 N/A

Is APLM or EQ more profitable?

Apollomics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Equillium N/A -61.43% -53.72%

Does the media prefer APLM or EQ?

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Equillium's score of 0.00 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate APLM or IPHA?

Innate Pharma has a consensus target price of $5.00, suggesting a potential upside of 177.78%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Innate Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, APLM or IPHA?

Apollomics has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Innate Pharma $10.19M 16.59 -$55.64M N/A N/A

Is APLM or IPHA more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Innate Pharma N/A N/A N/A

Does the media refer more to APLM or IPHA?

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Innate Pharma's score of 0.00 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer IMDX or APLM?

Oncocyte currently has a consensus target price of $12.00, suggesting a potential upside of 109.06%. Given Oncocyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncocyte is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncocyte 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, IMDX or APLM?

Apollomics has higher revenue and earnings than Oncocyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncocyte $4.05M 45.76 -$50.22M -$1.48 N/A Apollomics $8.50M 5.06 -$10.94M N/A N/A

Is IMDX or APLM more profitable?

Apollomics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% Apollomics N/A N/A N/A

Does the media favor IMDX or APLM?

In the previous week, Oncocyte had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Oncocyte and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Oncocyte's score of 0.00 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ACB or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ACB or APLM?

Apollomics has lower revenue, but higher earnings than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurora Cannabis $320.59M 0.54 -$88.13M -$1.56 N/A Apollomics $8.50M 5.06 -$10.94M N/A N/A

Does the media favor ACB or APLM?

In the previous week, Aurora Cannabis had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Aurora Cannabis and 1 mentions for Apollomics. Aurora Cannabis' average media sentiment score of 0.66 beat Apollomics' score of 0.59 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Apollomics (APLM) Competitors

$19.56 0.00 (0.00%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$18.62 -0.94 (-4.81%)

As of 07/2/2026 06:01 PM Eastern

Compare

APLM vs. DTIL, EQ, IPHA, IMDX, and ACB

Should you buy Apollomics stock or one of its competitors? MarketBeat compares Apollomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apollomics include Precision BioSciences (DTIL), Equillium (EQ), Innate Pharma (IPHA), Oncocyte (IMDX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.

How does Apollomics compare to Precision BioSciences?

Apollomics (NASDAQ:APLM) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Precision BioSciences had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.28 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apollomics has higher earnings, but lower revenue than Precision BioSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Precision BioSciences	$34.26M	6.16	-$45.72M	-$3.67	N/A

Apollomics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Precision BioSciences has a consensus target price of $32.25, indicating a potential upside of 294.25%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Apollomics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Apollomics' return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Precision BioSciences	-96.73%	-85.37%	-37.34%

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Precision BioSciences beats Apollomics on 8 of the 14 factors compared between the two stocks.

How does Apollomics compare to Equillium?

Apollomics (NASDAQ:APLM) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Apollomics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

Apollomics has higher earnings, but lower revenue than Equillium.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Equillium's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has a consensus price target of $7.57, indicating a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Apollomics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Equillium beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Apollomics compare to Innate Pharma?

Apollomics (NASDAQ:APLM) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Innate Pharma	N/A	N/A	N/A

Apollomics has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A

Innate Pharma has a consensus target price of $5.00, suggesting a potential upside of 177.78%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Innate Pharma's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apollomics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Innate Pharma beats Apollomics on 7 of the 11 factors compared between the two stocks.

How does Apollomics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Apollomics (NASDAQ:APLM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Apollomics has higher revenue and earnings than Oncocyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	45.76	-$50.22M	-$1.48	N/A
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A

Oncocyte has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Oncocyte currently has a consensus target price of $12.00, suggesting a potential upside of 109.06%. Given Oncocyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncocyte is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Apollomics	N/A	N/A	N/A

In the previous week, Oncocyte had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Oncocyte and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Oncocyte's score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Oncocyte beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Apollomics compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Aurora Cannabis has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has lower revenue, but higher earnings than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$320.59M	0.54	-$88.13M	-$1.56	N/A
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A

Apollomics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Apollomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-33.57%	0.10%	0.07%
Apollomics	N/A	N/A	N/A

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aurora Cannabis had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Aurora Cannabis and 1 mentions for Apollomics. Aurora Cannabis' average media sentiment score of 0.66 beat Apollomics' score of 0.59 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurora Cannabis beats Apollomics on 9 of the 13 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.96M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	5.06	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-6.77	8.66	10.96	6.46
Net Income	-$10.94M	$23.81M	$3.57B	$337.01M
7 Day Performance	-5.96%	3.39%	2.12%	1.69%
1 Month Performance	37.26%	10.81%	5.25%	3.81%
1 Year Performance	200.69%	62.61%	33.29%	23.90%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	0.7489 of 5 stars	$19.56 flat	N/A	+200.7%	$42.96M	$8.50M	N/A	45
DTIL Precision BioSciences	2.5437 of 5 stars	$7.01 +0.8%	$32.25 +360.4%	+87.0%	$180.73M	$34.26M	N/A	200	News Coverage Gap Down
EQ Equillium	2.8469 of 5 stars	$2.79 -1.9%	$7.57 +171.9%	+789.9%	$178.31M	$41.10M	N/A	40	News Coverage
IPHA Innate Pharma	2.1212 of 5 stars	$1.90 +0.3%	$5.00 +163.9%	-1.2%	$177.88M	$10.19M	N/A	220	News Coverage
IMDX Oncocyte	2.5547 of 5 stars	$5.41 +0.7%	$12.00 +122.0%	N/A	$176.72M	$1.95M	N/A	120	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. DTIL, EQ, IPHA, IMDX, and ACB

How does Apollomics compare to Precision BioSciences?

Summary

How does Apollomics compare to Equillium?

Summary

How does Apollomics compare to Innate Pharma?

Summary

How does Apollomics compare to Oncocyte?

Summary

How does Apollomics compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. DTIL, EQ, IPHA, IMDX, and ACB

How does Apollomics compare to Precision BioSciences?

Does the media prefer APLM or DTIL?

Which has preferable earnings & valuation, APLM or DTIL?

Which has more risk & volatility, APLM or DTIL?

Do analysts rate APLM or DTIL?

Is APLM or DTIL more profitable?

Do insiders and institutionals believe in APLM or DTIL?

Summary

How does Apollomics compare to Equillium?

Is APLM or EQ more profitable?

Which has preferable valuation and earnings, APLM or EQ?

Do institutionals & insiders believe in APLM or EQ?

Does the media prefer APLM or EQ?

Do analysts prefer APLM or EQ?

Which has more risk & volatility, APLM or EQ?

Summary

How does Apollomics compare to Innate Pharma?

Is APLM or IPHA more profitable?

Which has preferable earnings and valuation, APLM or IPHA?

Do analysts rate APLM or IPHA?

Does the media refer more to APLM or IPHA?

Which has more volatility and risk, APLM or IPHA?

Do institutionals and insiders believe in APLM or IPHA?

Summary

How does Apollomics compare to Oncocyte?

Which has higher earnings & valuation, IMDX or APLM?

Which has more volatility and risk, IMDX or APLM?

Do analysts prefer IMDX or APLM?

Is IMDX or APLM more profitable?

Does the media favor IMDX or APLM?

Do institutionals & insiders hold more shares of IMDX or APLM?

Summary

How does Apollomics compare to Aurora Cannabis?

Which has more volatility & risk, ACB or APLM?

Do analysts prefer ACB or APLM?

Which has preferable valuation & earnings, ACB or APLM?

Is ACB or APLM more profitable?

Do institutionals and insiders hold more shares of ACB or APLM?

Does the media favor ACB or APLM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools